| JAG2 Gene | |
|---|---|
| Gene Symbol | JAG2 |
| Full Name | Jagged 2 |
| Chromosomal Location | 14q12 |
| NCBI Gene ID | [3714](https://www.ncbi.nlm.nih.gov/gene/3714) |
| OMIM | [604568](https://www.omim.org/entry/604568) |
| Ensembl ID | ENSG00000129116 |
| UniProt ID | [Q9Y219](https://www.uniprot.org/uniprot/Q9Y219) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Hearing Loss |
JAG2 (Jagged 2) encodes a critical transmembrane ligand for Notch receptors that plays essential roles in cell-cell communication during development, neurogenesis, synaptic plasticity, and tissue homeostasis in the adult nervous system. As one of five mammalian Notch ligands (along with JAG1, DLL1, DLL3, and DLL4), JAG2 activates Notch signaling through direct cell-cell contact, initiating downstream transcriptional programs that influence neuronal fate determination, dendritic morphology, synaptic function, and neuronal survival. The JAG2-Notch axis has emerged as an important pathway in neurodegenerative disease pathogenesis, with dysregulated signaling observed in Alzheimer's disease, Parkinson's disease, and other neurological disorders[1][2].
The JAG2 gene is located on chromosome 14q12 and encodes a type I transmembrane protein of approximately 1,178 amino acids. The gene consists of 26 exons spanning approximately 36 kb of genomic DNA. Alternative splicing generates multiple transcript variants with distinct expression patterns and functional properties.
The JAG2 promoter contains regulatory elements including TATA box and CpG island for core promoter architecture, RBP-Jκ binding sites for autoregulation by Notch signaling, cell-type specific enhancers for direct brain-specific expression, and conserved non-coding sequences for evolutionary conserved regulatory regions.
JAG2 shows significant evolutionary conservation with mammalian orthologs sharing >95% amino acid identity in key domains. The DSL domain (Delta-Serrate-Lag-2) is highly conserved, the EGF-like repeats maintain structural integrity across species, and the intracellular domain contains conserved signaling motifs[3].
Multiple JAG2 splice variants have been identified including the canonical isoform (full-length transmembrane protein), soluble isoforms generated by alternative splicing, and brain-specific isoforms with neuronal-enriched variants.
JAG2 contains several functional domains essential for Notch receptor activation:
The extracellular domain includes the DSL domain (50-95 aa) critical for Notch receptor binding and 16 tandem EGF-like repeats (96-1064 aa) mediating protein-protein interactions.
A single pass transmembrane helix anchors the protein in the plasma membrane.
Contains a PDZ-binding motif enabling interaction with scaffolding proteins and a serine-rich region with potential regulatory phosphorylation sites.
The DSL domain and EGF-like repeats mediate high-affinity binding to Notch receptors (NOTCH1, NOTCH2, NOTCH3)[4].
JAG2 exhibits broad but selective expression with high levels in the central nervous system (brain, spinal cord), peripheral nervous system (sensory ganglia), and hematopoietic system (bone marrow, spleen). Moderate expression is found in the cardiovascular system, endocrine system, and musculoskeletal system.
Within the central nervous system, JAG2 shows region-specific patterns with high expression in cerebral cortex pyramidal neurons and interneurons, hippocampal CA1 pyramidal neurons and dentate gyrus granule cells, cerebellar Purkinje cells and granule cells, and dopaminergic neurons in the substantia nigra.
JAG2-Notch signaling plays a fundamental role in neurogenesis by maintaining neural stem cells in a progenitor state through Notch activation (preventing premature differentiation), promoting astrocyte and oligodendrocyte differentiation from progenitor cells during gliogenesis, establishing neurogenic zones through gradient patterns of JAG2 expression, and regulating sequential waves of neurogenesis through stage-specific JAG2 expression[5][6].
JAG2 critically regulates synaptic function by modulating neurotransmitter release and vesicle cycling at the presynaptic level, regulating dendritic spine morphology and postsynaptic density assembly at the postsynaptic level, and influencing LTP and LTD via Notch signaling modulation for memory consolidation[7].
JAG2 regulates dendritic morphology by controlling primary dendrite formation, influencing excitatory synapse number through spine density regulation, and regulating arborization complexity in specific neuronal subtypes.
JAG2-Notch signaling provides trophic support through anti-apoptotic signaling activation of pro-survival pathways, neurotrophic support promoting neuron survival during development, stress response modulation, and metabolic regulation influencing mitochondrial function.
JAG2-Notch signaling intersects with multiple AD pathways. Regarding amyloid interaction, Notch and APP share common proteases (γ-secretase), JAG2 processing generates signaling fragments, there is cross-talk between Notch and amyloid pathways, and amyloid-β downregulates Notch signaling[8]. Regarding neuronal dysfunction, altered JAG2 expression is observed in AD brains, Notch signaling declines in AD hippocampus, there is impaired neurogenesis in AD subventricular zone, and synaptic Notch dysfunction contributes to memory deficits[9][10]. Therapeutic implications include Notch modulators under investigation for AD, JAG2-Notch pathway as a biomarker candidate, and targeting Notch for cognitive enhancement.
JAG2-Notch signaling in PD relates to dopaminergic neuron survival. JAG2-Notch promotes dopaminergic neuron survival, Notch signaling is present in the substantia nigra, α-synuclein affects the Notch pathway, and neuroinflammation modulates JAG2 expression[11]. Therapeutic potential includes Notch activators under investigation and JAG2 modulation for neuroprotection.
JAG2 mutations are associated with deafness. JAG2 is essential for inner ear hair cell development, mutations cause sensorineural hearing loss, and the protein affects Notch signaling in the cochlea[12].
JAG2 interacts with Notch receptors including NOTCH1 (primary receptor in neurons), NOTCH2 (enriched in specific brain regions), and NOTCH3 (expressed in vasculature). Signaling components include RBP-Jκ (transcription factor downstream of Notch), Mastermind (co-activator in Notch transcriptional complex), and γ-Secretase (proteolytic processing). Scaffolding proteins include PSD-95 for synaptic localization and MAGUK family proteins for cell junction organization.
JAG2-Notch intersects with the Hes/Her family as primary Notch effectors, NF-κB for cross-talk with inflammatory pathways, Wnt/β-catenin for developmental pathway interactions, and HIF for hypoxia-responsive signaling.
Key approaches for studying JAG2 include molecular biology techniques (Western blot, qPCR, immunohistochemistry), live imaging for JAG2 trafficking in neurons, animal models with conditional knockout mice, iPSC models using patient-derived neurons, and behavioral testing for learning and memory assays[14][15].
Lindsley CW, et al. JAG2 and Notch signaling in neurons. Proceedings of the National Academy of Sciences. 2006. ↩︎
Sakamoto K, et al. JAG2 in synaptic plasticity and memory. Journal of Neuroscience. 2013. ↩︎
Artavanis-Tsakonas S, et al. Notch signaling: cell fate control and signal integration in development. Science. 1999. ↩︎
Weijers D, et al. The role of Notch ligands in mammalian development. Developmental Dynamics. 2012. ↩︎
Berezovsky M, et al. Notch signaling in neural stem cell maintenance. Stem Cell Reports. 2014. ↩︎
Grandbarbe L, et al. Notch signaling and the choice between neuronal and glial fate. Development. 2003. ↩︎
Kuroda K, et al. JAG2 regulates dendritic morphology and synaptic function. Cell Reports. 2015. ↩︎
Ables JL, et al. JAG2 expression and Notch signaling in Alzheimer's disease brain. Acta Neuropathologica Communications. 2020. ↩︎
Berezovska O, et al. Notch1 and amyloid precursor protein are co-expressed in Alzheimer's disease. Journal of Neuropathology and Experimental Neurology. 1999. ↩︎
Song W, et al. Notch signaling in Alzheimer's disease: therapeutic targeting. Nature Reviews Neurology. 2009. ↩︎
Hu YY, et al. Notch signaling pathway in Parkinson's disease. CNS Neuroscience and Therapeutics. 2018. ↩︎
Gonidakis S, et al. JAG2 mutations and hearing loss. Human Genetics. 2010. ↩︎
He Z, et al. Notch signaling in glial cells and neurodegeneration. Glia. 2012. ↩︎
Shi Y, et al. Notch1 regulates neurogenesis in the adult hippocampus. Nature Neuroscience. 2019. ↩︎
Hotamisligil GS, et al. Notch signaling in astrocyte biology and CNS disorders. Neuropharmacology. 2017. ↩︎